AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9703563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 8580278 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide enema (2 mg/100 mL)
Number of subjects: 97
Study 8580278 — intervention group
Group type: COMPARATOR
Intervention: 5-ASA enema (mesalazine 1 g/100 mL)
Number of subjects: 97
Study 2293938 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step application of a water-insoluble iodophor-in-alcohol solution
Number of subjects: 60
Study 2293938 — intervention group
Group type: COMPARATOR
Intervention: Traditional two-step method using aqueous iodophors (five-minute scrub followed by paint)
Number of subjects: 60
Study 2293938 — intervention group
Group type: COMPARATOR
Intervention: Traditional two-step method using aqueous iodophors
Number of subjects: 60
Study 33455 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone (3.5 mg/kg)
Number of subjects: 3
Study 33455 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone (1 mg/kg)
Number of subjects: 3
Study 33455 — intervention group
Group type: COMPARATOR
Intervention: Low-dose ketamine (1 mg/kg)
Number of subjects: 3
Study 31764794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball-point slide-type interbody distractor
Number of subjects: 59
Study 31764794 — intervention group
Group type: COMPARATOR
Intervention: Posterior reduction and internal fixation (control)
Number of subjects: 59
Study 27753282 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation 2
Number of subjects: 18
Study 27753282 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation 3
Number of subjects: 18
Study 27753282 — intervention group
Group type: COMPARATOR
Intervention: Innovator product
Number of subjects: 18
Study 26083828 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleph inactivated split influenza vaccine
Number of subjects: 641
Study 26083828 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (recombinant hepatitis B)
Number of subjects: 641
Study 23405952 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference parent training
Number of subjects: 22
Study 23405952 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face parent training
Number of subjects: 22
Study 20825844 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld feedback device
Number of subjects: 25
Study 20825844 — intervention group
Group type: COMPARATOR
Intervention: Control (no feedback device)
Number of subjects: 25
Study 20043525 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol 400 microg
Number of subjects: 140
Study 20043525 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular syntometrine (syntocinon 10 IU + ergometrine 0.5 mg)
Number of subjects: 140
Study 17374344 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled extract of Carum copticum (0.125 ml/kg and 0.25 ml/kg)
Number of subjects: 0
Study 17374344 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (6 mg/kg)
Number of subjects: 0
Study 17374344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15596918 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens in phase III clinical trials
Number of subjects: 0
Study 15596918 — intervention group
Group type: EXPERIMENTAL
Intervention: Response rates (RR) for most advanced cancers
Number of subjects: 0
Study 15596918 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders vs. nonresponders
Number of subjects: 0
Study 11717601 — intervention group
Group type: EXPERIMENTAL
Intervention: Duett vascular sealing device
Number of subjects: 0
Study 9150013 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic blockade with 0.5% epidural bupivacaine and 0.5‐1% isoflurane
Number of subjects: 40
Study 9150013 — intervention group
Group type: COMPARATOR
Intervention: Control group with nitrous/narcotic and inhalation anesthesia for maintenance
Number of subjects: 40
Study 7899032 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving random‐pixel arrays (RPAs) used to study MAE for translational texture motion.
Number of subjects: 0
Study 7899032 — intervention group
Group type: EXPERIMENTAL
Intervention: Subpopulation of local motion sensors contributing to the MAE.
Number of subjects: 0
Study 7899032 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of MAEs generated at different eccentricities.
Number of subjects: 0
Study 2949876 — intervention group
Group type: EXPERIMENTAL
Intervention: qi‐regulating; blood‐activating and wind‐dispelling Chinese medicine (A group, 100 cases)
Number of subjects: 232
Study 2949876 — intervention group
Group type: EXPERIMENTAL
Intervention: cortical hormone (B group, 51 cases)
Number of subjects: 232
Study 2949876 — intervention group
Group type: EXPERIMENTAL
Intervention: yin‐nourishing; blood‐activating and wind‐dispelling Chinese medicine (C group, 53 cases)
Number of subjects: 232
Study 2949876 — intervention group
Group type: COMPARATOR
Intervention: Buguzhi tincture (D group, 28 cases)
Number of subjects: 232
Study 29440005 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg·d‐1)
Number of subjects: 42
Study 29440005 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (1 mg·d‐1)
Number of subjects: 42
Study 29440005 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dapagliflozin and bumetanide
Number of subjects: 42
Study 29440005 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin after 1 week of bumetanide
Number of subjects: 42
Study 29440005 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide after 1 week of dapagliflozin
Number of subjects: 42
Study 29440005 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Dapagliflozin and Bumetanide)
Number of subjects: 42
Study 26446450 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrografin
Number of subjects: 58
Study 26446450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 23982766 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 51
Study 23982766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 22724534 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-Hz pulse-modulated radio frequency field
Number of subjects: 25
Study 22724534 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-Hz pulsed magnetic field
Number of subjects: 25
Study 22724534 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 25
Study 15882209 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary system containing block copolymers as toothpaste slurry rinse
Number of subjects: 21
Study 15882209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ternary system containing block copolymers and polypeptide as toothpaste slurry rinse
Number of subjects: 21
Study 15882209 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary system containing block copolymers as solution rinse
Number of subjects: 21
Study 15882209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ternary system containing block copolymers and polypeptide as solution rinse
Number of subjects: 21
Study 15882209 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional fluoride toothpaste rinse
Number of subjects: 21
Study 15882209 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine rinse (positive control)
Number of subjects: 21
Study 15882209 — intervention group
Group type: COMPARATOR
Intervention: Water rinse (negative control)
Number of subjects: 21
Study 12186234 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape of an expert model performing the skills
Number of subjects: 116
Study 12186234 — intervention group
Group type: COMPARATOR
Intervention: Videotaped replay of their own performance
Number of subjects: 116
Study 10192700 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade oligodendroglial tumors
Number of subjects: 47
Study 10192700 — intervention group
Group type: COMPARATOR
Intervention: Low-grade oligodendroglial tumors
Number of subjects: 47
Study 7775634 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone 2.5 mg daily
Number of subjects: 16
Study 7775634 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone 50 mg monthly IM injections
Number of subjects: 16
Study 7775634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7775634 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatments (Oxandrolone and Testosterone)
Number of subjects: 16
Study 7775634 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (including placebo)
Number of subjects: 16
Study 2270749 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential fatty acid therapy (8 x 500 mg capsules per day for 3 months)
Number of subjects: 63
Study 2270749 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8 x 500 mg capsules per day for 3 months)
Number of subjects: 63
Study 7009192 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (250 microgram for women, 500 microgram for men)
Number of subjects: 3
Study 7009192 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic mist of H2O (group 1)
Number of subjects: 3
Study 7009192 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise on cycloergometer (group 2)
Number of subjects: 3
Study 7009192 — intervention group
Group type: COMPARATOR
Intervention: Pneumoallergens (group 3)
Number of subjects: 3
Study 31813550 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed suture for closure of enterocolotomy
Number of subjects: 80
Study 30276208 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure S (shallow puncture angle using a guidance system)
Number of subjects: 40
Study 30276208 — intervention group
Group type: COMPARATOR
Intervention: Procedure C (conventional free-hand method)
Number of subjects: 40
Study 30276208 — intervention group
Group type: COMPARATOR
Intervention: Procedure N (needle navigation system)
Number of subjects: 40
Study 27342264 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin testing
Number of subjects: 111
Study 24176494 — intervention group
Group type: EXPERIMENTAL
Intervention: PhtD 30 μg plus AS02V
Number of subjects: 297
Study 24176494 — intervention group
Group type: EXPERIMENTAL
Intervention: PhtD 10 μg plus alum
Number of subjects: 297
Study 24176494 — intervention group
Group type: EXPERIMENTAL
Intervention: PhtD 30 μg plus alum
Number of subjects: 297
Study 24176494 — intervention group
Group type: EXPERIMENTAL
Intervention: PhtD 10 μg plus AS02V
Number of subjects: 297
Study 24176494 — intervention group
Group type: COMPARATOR
Intervention: Alum adjuvant
Number of subjects: 297
Study 24176494 — intervention group
Group type: COMPARATOR
Intervention: 23-valent polysaccharide pneumococcal vaccine (23PPV)
Number of subjects: 297
Study 24176494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 297
Study 23962655 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbations towards the preferred leg
Number of subjects: 39
Study 23962655 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbations towards the non-preferred leg
Number of subjects: 39
Study 21990397 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + bevacizumab
Number of subjects: 684
Study 21990397 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy + placebo
Number of subjects: 684
Study 19067098 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm Minimization (HM) curriculum in grades 8 and 9
Number of subjects: 5266
Study 19067098 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Skills Training (LST) curriculum in grades 8 and 9
Number of subjects: 5266
Study 19067098 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual tobacco use education)
Number of subjects: 5266
Study 16151770 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory-provoked rCBF-SPECT (MP-SPECT)
Number of subjects: 36
Study 16151770 — intervention group
Group type: COMPARATOR
Intervention: Rest rCBF-SPECT
Number of subjects: 36
Study 12970130 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled second endoscopy 16-24 hours after initial haemostasis
Number of subjects: 194
Study 12970130 — intervention group
Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 194
Study 12970130 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled second endoscopy
Number of subjects: 194
Study 10709150 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. verapamil
Number of subjects: 84
Study 10709150 — intervention group
Group type: EXPERIMENTAL
Intervention: oral verapamil
Number of subjects: 84
Study 10709150 — intervention group
Group type: EXPERIMENTAL
Intervention: 14C‐erythromycin breath tests (ERBT)
Number of subjects: 84
Study 10709150 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. and p.o. verapamil
Number of subjects: 84
Study 10709150 — intervention group
Group type: EXPERIMENTAL
Intervention: p.o. verapamil
Number of subjects: 84
Study 9166816 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyskon (250 ml 32% dextran 70)
Number of subjects: 13
Study 9166816 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (250 ml)
Number of subjects: 13
Study 9166816 — intervention group
Group type: COMPARATOR
Intervention: Control (no fluid)
Number of subjects: 13
Study 1584259 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor (intracervical application of prostaglandin E2)
Number of subjects: 3407
Study 1584259 — intervention group
Group type: COMPARATOR
Intervention: Serial antenatal monitoring (counts of fetal kicks, nonstress tests, assessments of amniotic-fluid volume)
Number of subjects: 3407
Study 1584259 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 3407
Study 1584259 — intervention group
Group type: COMPARATOR
Intervention: Serial antenatal monitoring
Number of subjects: 3407
Study 1584259 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor and Serial antenatal monitoring
Number of subjects: 3407
Study 3898904 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hyposensitization with timothy whole pollen (4,315,000 PNU preseasonally and 8,915,000 PNU total for 6 months)
Number of subjects: 58
Study 3898904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 30587191 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based weight management and healthy lifestyle service for 6 months
Number of subjects: 120
Study 30587191 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 120
Study 29786336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 2.5-3.0 mL human umbilical cord MSCs suspension containing (2-3)×10^7 cells, once a month for 2 times
Number of subjects: 36
Study 29786336 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate by intra-articular injection, once a week for 5 times
Number of subjects: 36
Study 23941193 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric-concentric exercise program of the ankle evertors and dorsiflexors, performed 3 days per week for 6 weeks
Number of subjects: 24
Study 23941193 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric-concentric exercise program of the ankle evertors and dorsiflexors
Number of subjects: 24
Study 23941193 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 22471128 — intervention group
Group type: EXPERIMENTAL
Intervention: Coiling dragon needling and moving cupping
Number of subjects: 72
Study 22471128 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (10 mg orally, once daily for 2 courses)
Number of subjects: 72
Study 20921898 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa 2a 180 mcg per week + weight-based ribavirin for 12 weeks, followed by full dose PEG for 72 weeks
Number of subjects: 330
Study 20921898 — intervention group
Group type: COMPARATOR
Intervention: Observation only for 72 weeks
Number of subjects: 330
Study 18655992 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigamox 4 times 1 day before surgery plus 1 drop 2 hours preoperatively (Group 1)
Number of subjects: 74
Study 18655992 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigamox 2 hours before surgery and every 15 minutes in the first hour only (Group 2)
Number of subjects: 74
Study 15875961 — intervention group
Group type: EXPERIMENTAL
Intervention: Preadmission videotape presentation
Number of subjects: 141
Study 15875961 — intervention group
Group type: COMPARATOR
Intervention: No videotape presentation (Control)
Number of subjects: 141
Study 12622686 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention (motivational message, guide to quitting, 10-minute motivational interview, and up to 3 outreach calls in 3 months)
Number of subjects: 303
Study 12622686 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 303
Study 12622686 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 303
Study 10575171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular preexposure vaccination
Number of subjects: 138
Study 10575171 — intervention group
Group type: COMPARATOR
Intervention: Intradermal preexposure vaccination (0.1 mL dose)
Number of subjects: 138
Study 10575171 — intervention group
Group type: EXPERIMENTAL
Intervention: All study subjects
Number of subjects: 138
Study 8793607 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole and 100 mg diclofenac
Number of subjects: 24
Study 8793607 — intervention group
Group type: COMPARATOR
Intervention: 100 mg diclofenac
Number of subjects: 24
Study 8793607 — intervention group
Group type: COMPARATOR
Intervention: 40 mg pantoprazole
Number of subjects: 24
Study 1928632 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZ; 4‐28 mg)
Number of subjects: 27
Study 1928632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 27
Study 1928632 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective drug effects
Number of subjects: 27
Study 7047258 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (600 mg daily)
Number of subjects: 55
Study 7047258 — intervention group
Group type: COMPARATOR
Intervention: Tiapride
Number of subjects: 55
Study 30789154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ba-Duan-Jin
Number of subjects: 62
Study 30789154 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study 28673494 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 50
Study 28673494 — intervention group
Group type: COMPARATOR
Intervention: Calcium Hydroxide (CH)
Number of subjects: 50
Study 26038159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol <10mM
Number of subjects: 10
Study 26038159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol <20mM
Number of subjects: 10
Study 26038159 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (APZ, 1mg)
Number of subjects: 10
Study 26038159 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem (ZLP, 10mg)
Number of subjects: 10
Study 23821759 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab added to oxaliplatin-based standard adjuvant chemotherapy regimen
Number of subjects: 0
Study 23821759 — intervention group
Group type: COMPARATOR
Intervention: Standard adjuvant chemotherapy regimen without bevacizumab
Number of subjects: 0
Study 22576838 — intervention group
Group type: EXPERIMENTAL
Intervention: Charnley total hip arthroplasty (THA)
Number of subjects: 35
Study 18829069 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive patch (20 microg ethinylestradiol + 150 microg norelgestromin daily)
Number of subjects: 13
Study 18829069 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring (15 microg ethinylestradiol + 120 microg etonogestrel daily)
Number of subjects: 13
Study 18829069 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive (30 microg ethinylestradiol + 150 microg levonorgestrel daily)
Number of subjects: 13
Study 17173849 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbal‐conjunctival autograft transplantation (LCAT)
Number of subjects: 27
Study 17173849 — intervention group
Group type: COMPARATOR
Intervention: Amniotic membrane transplantation (AMT)
Number of subjects: 27
Study 14712334 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (2 mg bolus injection)
Number of subjects: 12
Study 14712334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11549528 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone, 20 mg/d for 2 weeks
Number of subjects: 28
Study 11549528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9802142 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/d
Number of subjects: 143
Study 9802142 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 143
Study 9802142 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg/d + Warfarin
Number of subjects: 143
Study 9802142 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143
Study 9802142 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/d (2 h after intake)
Number of subjects: 143
Study 9802142 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (14 patients identified as secondary aspirin non-responders)
Number of subjects: 143
Study 9802142 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (2 patients identified as primary aspirin non-responders)
Number of subjects: 143
Study 7526006 — intervention group
Group type: EXPERIMENTAL
Intervention: Urolase right angle firing neodymium:YAG laser fiber
Number of subjects: 25
Study 7526006 — intervention group
Group type: COMPARATOR
Intervention: Standard transurethral electroresection of the prostate
Number of subjects: 25
Study 7526006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 25
Study 2682160 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization treatment
Number of subjects: 39
Study 2682160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 4601308 — intervention group
Group type: EXPERIMENTAL
Intervention: iv inosine, pyruvate, and inorganic phosphate (IPP)
Number of subjects: 10
Study 4601308 — intervention group
Group type: COMPARATOR
Intervention: iv saline
Number of subjects: 10
Study 29911503 — intervention group
Group type: EXPERIMENTAL
Intervention: Audience response systems
Number of subjects: 70
Study 29911503 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard methods)
Number of subjects: 70